Market Place
Sourcing Support
CorMedix Inc. Announces New Data at ASN Kidney Week 2024
24 Oct 2024 //
GLOBENEWSWIRE
CorMedix Q3 2024 Financial Results on October 30
23 Oct 2024 //
GLOBENEWSWIRE
CorMedix Announces Agreement With Mid-Sized Dialysis Operator
08 Oct 2024 //
GLOBENEWSWIRE
CorMedix Inc. Announces New Commercial Agreement
19 Sep 2024 //
GLOBENEWSWIRE
CorMedix Inc. to Present at the Cantor Global Healthcare Conference
13 Sep 2024 //
GLOBENEWSWIRE
CorMedix Inc. Announces New Commercial Agreement
09 Sep 2024 //
GLOBENEWSWIRE
CorMedix Reports Q2 2024 Financial Results And Business Update
14 Aug 2024 //
GLOBENEWSWIRE
CorMedix To Report Q2 2024 Results And Update On August 14
07 Aug 2024 //
GLOBENEWSWIRE
CorMedix Inc. Announces Outpatient Availability of DefenCath
03 Jul 2024 //
GLOBENEWSWIRE
CorMedix Receives FDA Feedback On Label Expansion
18 Jun 2024 //
GLOBENEWSWIRE
CorMedix Inc. Announces CMS Grants Pass-Through Status to Defencath
06 Jun 2024 //
GLOBENEWSWIRE
CorMedix Inc. Announces Commercial Agreement With Top Tier Dialysis Provider
28 May 2024 //
GLOBENEWSWIRE
CorMedix Inc. to Participate in Two Upcoming Investor Conferences
10 May 2024 //
GLOBENEWSWIRE
CorMedix Inc. Reports First Quarter 2024 Financial Results
09 May 2024 //
GLOBENEWSWIRE
CorMedix To Report Q1 2024 Results, Corporate Update On May 9
06 May 2024 //
GLOBENEWSWIRE
CorMedix Inc. Announces CMS Grants TDAPA to DefenCath
19 Apr 2024 //
GLOBENEWSWIRE
CorMedix: DefenCath® Now Commercially Available In US
15 Apr 2024 //
GLOBENEWSWIRE
CorMedix Abstracts At Healthcare Epidemiology Society Conference
11 Apr 2024 //
GLOBENEWSWIRE
CorMedix Announces Commercial Agreement With ARC Dialysis, LLC
08 Apr 2024 //
GLOBENEWSWIRE
CorMedix Inc. to Present at the Needham Annual Healthcare Conference
27 Mar 2024 //
GLOBENEWSWIRE
CorMedix Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
12 Mar 2024 //
GLOBENEWSWIRE
CorMedix Inc. to Report Fourth Quarter and Full Year 2023 Financial Results
06 Mar 2024 //
GLOBENEWSWIRE
CorMedix Inc. Announces Commercial and Reimbursement Updates
30 Jan 2024 //
GLOBENEWSWIRE
CorMedix Inc. Announces Commercial and Operational Updates
08 Jan 2024 //
GLOBENEWSWIRE
CorMedix Inc. Announces Appointment of Chief Legal Officer
15 Dec 2023 //
GLOBENEWSWIRE
CorMedix Inc. Announces Partnership With The Leapfrog Group
04 Dec 2023 //
GLOBENEWSWIRE
US FDA approves CorMedix`s drug for bloodstream infections
16 Nov 2023 //
REUTERS
CorMedix Inc. Reports Third Quarter and Nine Month 2023 Financial Results
14 Nov 2023 //
GLOBENEWSWIRE
CorMedix Inc. to Report Third Quarter 2023 Financial Results
02 Nov 2023 //
GLOBENEWSWIRE
CorMedix Inc. Announces Abstract Presentation at Upcoming IDWeek Conference
11 Oct 2023 //
GLOBENEWSWIRE
CorMedix Inc. to Present at the Cantor Fitzgerald Global Healthcare Conference
26 Sep 2023 //
GLOBENEWSWIRE
CorMedix Inc. Announces Publication of Phase 3 LOCK IT-100 Study Data
08 Sep 2023 //
GLOBENEWSWIRE
CorMedix to Present at the H.C. Wainwright Annual Global Investment Conference
06 Sep 2023 //
GLOBENEWSWIRE
CorMedix Inc. Announces Issuance of U.S. Patent Covering Lead Product Defencath
30 Aug 2023 //
GLOBENEWSWIRE
CorMedix Inc. Reports Second Quarter and Six Month 2023 Financial Results
08 Aug 2023 //
GLOBENEWSWIRE
CorMedix Inc. to Report Second Quarter 2023 Financial Results
26 Jul 2023 //
GLOBENEWSWIRE
CorMedix Inc. Announces Proposed PO of Common Stock and Pre-Funded Warrants
28 Jun 2023 //
GLOBENEWSWIRE
CorMedix Inc. Announces Pricing of $40 Million Public Offering
28 Jun 2023 //
GLOBENEWSWIRE
CorMedix Announces FDA Acceptance of Resubmission of NDA for DefenCath
21 Jun 2023 //
GLOBENEWSWIRE
Cormedix Announces Strategic Initiative With Boston Med Center to Reduce Health
15 Jun 2023 //
GLOBENEWSWIRE
Cormedix Inc. To Present At The Jefferies Healthcare Conference
30 May 2023 //
GLOBENEWSWIRE
CorMedix Inc. Announces Resubmission of New Drug Application for DefenCath
16 May 2023 //
GLOBENEWSWIRE
CorMedix Inc. Reports 1Q 2023 FYR Results and Provides Business Update
15 May 2023 //
GLOBENEWSWIRE
CorMedix Inc. To Report 1Q 2023 FYR and Provide Update on May 15, 2023
08 May 2023 //
GLOBENEWSWIRE
CorMedix Inc. to Participate in Two Upcoming Investor Conferences
03 May 2023 //
GLOBENEWSWIRE
CorMedix Inc. Announces Notice of Allowance for U.S. Patent Application
01 May 2023 //
GLOBENEWSWIRE
CorMedix Inc. Announces Regulatory, Manufacturing and Reimbursement Updates
26 Apr 2023 //
GLOBENEWSWIRE
Cormedix Inc. Announces Appointment of Robert A. Stewart to Its BOD
17 Apr 2023 //
GLOBENEWSWIRE
CorMedix Inc. Reports 4Q and Full Reports Full 2022 FYR
30 Mar 2023 //
GLOBENEWSWIRE
Cormedix Inc. to Report Fourth Quarter and Fiscal Year 2022 Financial Results
21 Mar 2023 //
GLOBENEWSWIRE
CorMedix Inc. Announces Regulatory and Manufacturing Updates
02 Mar 2023 //
GLOBENEWSWIRE
CorMedix Inc. Announces Promotions in Commercial and Tech Ops
17 Jan 2023 //
GLOBENEWSWIRE
Cormedix Announces Presentation at Conference Showing Mortality Risk
06 Dec 2022 //
GLOBENEWSWIRE
CorMedix Inc. Reports 3Q 2022 Financial Results and Provides Business Update
10 Nov 2022 //
GLOBENEWSWIRE
CorMedix Inc. Announces CMS Revision to NTAP Reimbursement of DefenCath
07 Nov 2022 //
GLOBENEWSWIRE
CorMedix Inc. to Report Third Quarter 2022 Financial Results
02 Nov 2022 //
GLOBENEWSWIRE
CorMedix Inc. Announces Abstract Presentation at Conference
20 Oct 2022 //
GLOBENEWSWIRE
CorMedix Inc. to Present at the H.C. Wainwright Annual GIC
07 Sep 2022 //
GLOBENEWSWIRE
Cormedix Inc. Reports Second Quarter And Six Month 2022 Financial Results
11 Aug 2022 //
PRESS RELEASE
CorMedix hit with second CRL for antifungal treatment, citing various issues
10 Aug 2022 //
ENDPTS
